The P2 Receptors in Platelet Function

ABSTRACT

After vessel wall injury, platelets adhere to the exposed subendothelium, are activated, and release mediators such as thromboxane A₂ (TXA₂) and nucleotides stored at very high concentration in the so-called dense granules. Among other soluble agents, released nucleotides act in a positive feedback mechanism to cause further platelet activation and amplify platelet responses induced by agents such as thrombin or collagen. Adenine nucleotides act on platelets through three distinct P2 receptors: two are G protein-coupled adenosine diphosphate (ADP) receptors, namely the P2Y₁ and P2Y₁₂ receptor subtypes; the P2X₁ receptor ligand-gated cation channel is activated by adenosine triphosphate (ATP). The P2Y₁ receptor initiates platelet aggregation but is not sufficient for a full platelet aggregation in response to ADP, whereas the P2Y₁₂ receptor is responsible for completion of the aggregation to ADP. This receptor, the molecular target of the antithrombotic drug clopidogrel, is responsible for most of the potentiating effects of ADP when platelets are stimulated by agents such as thrombin, collagen, or immune complexes. The P2X₁ receptor is involved in platelet shape change and in activation by collagen under shear conditions. Each of these receptors is coupled to specific signal transduction pathways in response to ADP or ATP and is differentially involved in all of the sequential events involved in platelet function and hemostasis. As such, they represent potential targets for antithrombotic drugs.

KEYWORDS

Signal transduction - hemostasis - nucleotides - thrombosis

REFERENCES

• 1 Cattaneo M, Canciani M T, Lecchi A et al.. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates.  Blood. 1990;  75 1081-1086
• 2 Kinlough-Rathbone R L, Packham M A, Perry D W et al.. Lack of stability of aggregates after thrombin-induced reaggregation of thrombin-degranulated platelets.  Thromb Haemost. 1992;  67 453-457
• 3 Lau L F, Pumiglia K, Cote Y P, Feinstein M B. Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators.  Biochem J. 1994;  303 391-400
• 4 Macfarlane D E, Srivastava P C, Mills D C. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets.  J Clin Invest. 1983;  71 420-428
• 5 Lanza F, Beretz A, Stierle A et al.. Epinephrine potentiates human platelet activation but is not an aggregating agent.  Am J Physiol. 1988;  255 H1276-H1288
• 6 Clemetson K J, Clemetson J M, Proudfoot A E et al.. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets.  Blood. 2000;  96 4046-4054
• 7 Kowalska M A, Ratajczak M Z, Majka M et al.. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets.  Blood. 2000;  96 50-57
• 8 Cusack N J, Hourani S M. Platelet P2 receptors: from curiosity to clinical targets.  J Auton Nerv Syst. 2000;  81 37-43
• 9 Humphries R G. Pharmacology of AR-C69931MX and related compounds: from pharmacological tools to clinical trials.  Haematologica. 2000;  85 66-72
• 10 Herbert J M, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel.  Semin Vasc Med. 2003;  3 113-122
• 11 Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders.  Arterioscler Thromb Vasc Biol. 1999;  19 2281-2285
• 12 Cattaneo M. Congenital disorders of platelet secretion. In: Gresele P, Page C, Fuster V, Vermylen J Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge, UK; Cambridge University Press 2002: 655-673
• 13 Zawilska K M, Born G V, Begent N A. Effect of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits.  Br J Haematol. 1982;  50 317-325
• 14 Marcus A, Broekman M, Drosopoulos J et al.. Thromboregulation by endothelial cells: significance for occlusive vascular diseases.  Arterioscler Thromb Vasc Biol. 2001;  21 178-182
• 15 Enjyoji K, Sevigny J, Lin Y et al.. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.  Nat Med. 1999;  5 1010-1017
• 16 Gachet C. ADP receptors of platelets and their inhibition.  Thromb Haemost. 2001;  86 222-232
• 17 Rolf M G, Brearley C A, Mahaut-Smith M P. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP.  Thromb Haemost. 2001;  85 303-308
• 18 Mahaut-Smith M P, Tolhurst G, Evans R J. Emerging roles for P2X1 receptors in platelet activation.  Platelets. 2004;  15 131-144
• 19 Ralevic V, Burnstock G. Receptors for purines and pyrimidines.  Pharmacol Rev. 1998;  50 413-492
• 20 Khakh B S, Burnstock G, Kennedy C et al.. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits.  Pharmacol Rev. 2001;  53 107-118
• 21 Communi D, Janssens R, Suarez-Huerta N et al.. Advances in signalling by extracellular nucleotides. The role and transduction mechanisms of P2Y receptors.  Cell Signal. 2000;  12 351-360
• 22 Shaver S R. P2Y receptors: biological advances and therapeutic opportunities.  Curr Opin Drug Discov Devel. 2001;  4 665-670
• 23 Abbracchio M P, Boeynaems J M, Barnard E A et al.. Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family.  Trends Pharmacol Sci. 2003;  24 52-55
• 24 Hollopeter G JH, Vincent D, Li G et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature. 2001;  409 202-207
• 25 Savi P, Labouret C, Delesque N et al.. P2y(12), a new platelet ADP receptor, target of clopidogrel.  Biochem Biophys Res Commun. 2001;  283 379-383
• 26 Léon C, Hechler B, Freund M et al.. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.  J Clin Invest. 1999;  104 1731-1737
• 27 Fabre J E, Nguyen M, Latour A et al.. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.  Nat Med. 1999;  5 1199-1202
• 28 Oury C, Toth-Zsamboki E, Thys C et al.. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen.  Thromb Haemost. 2001;  86 1264-1271
• 29 Hechler B, Lenain N, Marchese P et al.. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo.  J Exp Med. 2003;  198 661-667
• 30 Oury C, Sticker E, Cornelissen H et al.. ATP augments vWF-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation.  J Biol Chem. 2004;  279 26266-26273
• 31 Cattaneo M, Marchese P, Jacobson K A, Ruggeri Z. New insights into the role of P2X1 in platelet function.  Haematologica. 2002;  87 13-14
• 32 Léon C, Hechler B, Vial C et al.. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells.  FEBS Lett. 1997;  403 26-30
• 33 Hechler B, Léon C, Vial C et al.. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation.  Blood. 1998;  92 152-159
• 34 Webb T E, Simon J, Krishek B J et al.. Cloning and functional expression of a brain G-protein-coupled ATP receptor.  FEBS Lett. 1993;  324 219-225
• 35 Léon C, Vial C, Cazenave J P, Gachet C. Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor.  Gene. 1996;  171 295-297
• 36 Hechler B, Vigne P, Léon C et al.. ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor.  Mol Pharmacol. 1998;  53 727-733
• 37 Palmer R K, Boyer J L, Schachter J B et al.. Agonist action of adenosine triphosphates at the human P2Y1 receptor.  Mol Pharmacol. 1998;  54 1118-1123
• 38 Waldo G L, Harden T K. Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor.  Mol Pharmacol. 2004;  65 426-436
• 39 Boyer J L, Romero-Avila T, Schachter J B, Harden T K. Identification of competitive antagonists of the P2Y1 receptor.  Mol Pharmacol. 1996;  50 1323-1329
• 40 Boyer J L, Mohanram A, Camaioni E et al.. Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'- deoxyadenosine 3′,5′-bisphosphate.  Br J Pharmacol. 1998;  124 1-3
• 41 Baurand A, Raboisson P, Freund M et al.. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.  Eur J Pharmacol. 2001;  412 213-221
• 42 Baurand A, Gachet C. The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179.  Cardiovasc Drug Rev. 2003;  21 67-76
• 43 Boyer J L, Adams M, Ravi R G et al.. 2-chloro N(6)-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate is a selective high affinity P2Y(1) receptor antagonist.  Br J Pharmacol. 2002;  135 2004-2010
• 44 Jin J, Daniel J L, Kunapuli S P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets.  J Biol Chem. 1998;  273 2030-2034
• 45 Savi P, Beauverger P, Labouret C et al.. Role of P2Y1 purinoceptor in ADP-induced platelet activation.  FEBS Lett. 1998;  422 291-295
• 46 Hechler B, Eckly A, Ohlmann P et al.. The P2Y1 receptor, necessary but not sufficient to support full ADP- induced platelet aggregation, is not the target of the drug clopidogrel.  Br J Haematol. 1998;  103 858-866
• 47 Bauer M, Retzer M, Wilde J I et al.. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets.  Blood. 1999;  94 1665-1672
• 48 Klages B, Brandt U, Simon M I et al.. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets.  J Cell Biol. 1999;  144 745-754
• 49 Paul B Z, Daniel J L, Kunapuli S P. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change.  J Biol Chem. 1999;  274 28293-28300
• 50 Sage S O, Reast R, Rink T J. ADP evokes biphasic Ca2+ influx in fura-2-loaded human platelets. Evidence for Ca2+ entry regulated by the intracellular Ca2+ store.  Biochem J. 1990;  265 675-680
• 51 Offermanns S, Toombs C F, Hu Y H, Simon M I. Defective platelet activation in G alpha(q)-deficient mice.  Nature. 1997;  389 183-186
• 52 Ohlmann P, Eckly A, Freund M et al.. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq.  Blood. 2000;  96 2134-2139
• 53 Wilde J I, Retzer M, Siess W, Watson S P. ADP-induced platelet shape change: an investigation of the signalling pathways involved and their dependence on the method of platelet preparation.  Platelets. 2000;  11 286-295
• 54 Cattaneo M, Lecchi A, Randi A M et al.. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.  Blood. 1992;  80 2787-2796
• 55 Nurden P, Savi P, Heilmann E et al.. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.  J Clin Invest. 1995;  95 1612-1622
• 56 Hechler B, Zhang Y, Eckly A et al.. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice.  J Thromb Haemost. 2003;  1 155-163
• 57 Mangin P, Ohlmann P, Eckly A et al.. The P2Y receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented.  J Thromb Haemost. 2004;  2 969-977
• 58 Eckly A, Gendrault J L, Hechler B et al.. Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation.  Thromb Haemost. 2001;  85 694-701
• 59 Gachet C, Hechler B. The platelet P2 receptors in thrombosis.  Semin Thromb Hemost. 2005;  31 162-167
• 60 Fagura M S, Dainty I A, McKay G D et al.. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.  Br J Pharmacol. 1998;  124 157-164
• 61 Geiger J, Brich J, Honig-Liedl P et al.. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.  Arterioscler Thromb Vasc Biol. 1999;  19 2007-2011
• 62 Jantzen H M, Gousset L, Bhaskar V et al.. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation.  Thromb Haemost. 1999;  81 111-117
• 63 Daniel J L, Dangelmaier C, Jin J et al.. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets.  J Biol Chem. 1998;  273 2024-2029
• 64 Léon C, Vial C, Gachet C et al.. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation.  Thromb Haemost. 1999;  81 775-781
• 65 Zhang F L, Luo L, Gustafson E et al.. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999.  J Biol Chem. 2001;  276 8608-8615
• 66 Unterberger U, Moskvina E, Scholze T et al.. Inhibition of adenylyl cyclase by neuronal P2Y receptors.  Br J Pharmacol. 2002;  135 673-684
• 67 Simon J, Vigne P, Eklund K M et al.. Activity of adenosine diphosphates and triphosphates on a P2Y(T) -type receptor in brain capillary endothelial cells.  Br J Pharmacol. 2001;  132 173-182
• 68 Takasaki J, Kamohara M, Saito T et al.. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor.  Mol Pharmacol. 2001;  60 432-439
• 69 Cusack N J, Hourani S M. Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors.  Br J Pharmacol. 1982;  76 221-227
• 70 Cusack N J, Hourani S M. Adenosine, adenine nucleotides, and platelet function. In: Phillis JW Adenosine and Adenine Nucleotides as Regulators of Cellular Function. Boca Raton, FL; CRC Press 1991: 121-131
• 71 Park H S, Hourani S M. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.  Br J Pharmacol. 1999;  127 1359-1366
• 72 Kauffenstein G, Hechler B, JP C, Gachet C. Adenine triphosphate nucleotides are antagonists at the P2Y12 receptor.  J Thromb Haemost. 2004;  2 1980-1988
• 73 Bodor E T, Waldo G L, Hooks S B et al.. Purification and functional reconstitution of the human P2Y12 receptor.  Mol Pharmacol. 2003;  64 1210-1216
• 74 Ingall A H, Dixon J, Bailey A et al.. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.  J Med Chem. 1999;  42 213-220
• 75 Cattaneo M, Zighetti M L, Lombardi R et al.. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding.  Proc Natl Acad Sci U S A. 2003;  100 1978-1983
• 76 Cattaneo M, Lecchi A, Lombardi R et al.. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet ‘primary secretion defect’ are heterozygous for a defect of P2CYC receptors.  Arterioscler Thromb Vasc Biol. 2000;  20 E101-E106
• 77 Foster C J, Prosser D M, Agans J M et al.. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.  J Clin Invest. 2001;  107 1591-1598
• 78 Andre P, Delaney S M, LaRocca T et al.. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries.  J Clin Invest. 2003;  112 398-406
• 79 Nieswandt B, Schulte V, Zywietz A et al.. Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets.  J Biol Chem. 2002;  277 39493-39498
• 80 Dorsam R T, Kim S, Jin J, Kunapuli S P. Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets.  J Biol Chem. 2002;  277 47588-47595
• 81 Polgar J, Eichler P, Greinacher A, Clemetson K J. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients.  Blood. 1998;  91 549-554
• 82 Gratacap M P, Herault J P, Viala C et al.. FcgammaRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation.  Blood. 2000;  96 3439-3446
• 83 Saci A, Pain S, Rendu F, Bachelot-Loza C. Fc receptor-mediated platelet activation is dependent on phosphatidylinositol 3-kinase activation and involves p120(Cbl).  J Biol Chem. 1999;  274 1898-1904
• 84 Gratacap M P, Payrastre B, Viala C et al.. Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-gamma2 is an early key event in FcgammaRIIA-mediated activation of human platelets.  J Biol Chem. 1998;  273 24314-24321
• 85 Chacko G W, Brandt J T, Coggeshall K M, Anderson C L. Phosphoinositide 3-kinase and p72syk noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine-based activation motif. Reconstitution with synthetic phosphopeptides.  J Biol Chem. 1996;  271 10775-10781
• 86 Nieswandt B, Bergmeier W, Eckly A et al.. Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation.  Blood. 2001;  97 3829-3835
• 87 Cattaneo M, Lombardi R, Zighetti M L et al.. Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production.  Thromb Haemost. 1997;  77 986-990
• 88 Cattaneo M. The P2 receptors and congenital platelet function defects.  Semin Thromb Hemost. 2005;  31 168-173
• 89 Trumel C, Payrastre B, Plantavid M et al.. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase.  Blood. 1999;  94 4156-4165
• 90 Humbert M, Nurden P, Bihour C et al.. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation.  Arterioscler Thromb Vasc Biol. 1996;  16 1532-1543
• 91 Ohlmann P, Laugwitz K L, Nurnberg B et al.. The human platelet ADP receptor activates Gi2 proteins.  Biochem J. 1995;  312 775-779
• 92 Jantzen H M, Milstone D S, Gousset L et al.. Impaired activation of murine platelets lacking G alpha(i2).  J Clin Invest. 2001;  108 477-483
• 93 Haslam R J. Interactions of the pharmacological receptors of blood platelets with adenylate cyclase.  Ser Haematol. 1973;  6 333-350
• 94 Savi P, Pflieger A M, Herbert J M. cAMP is not an important messenger for ADP-induced platelet aggregation.  Blood Coagul Fibrinolysis. 1996;  7 249-252
• 95 Daniel J L, Dangelmaier C, Jin J et al.. Role of intracellular signaling events in ADP-induced platelet aggregation.  Thromb Haemost. 1999;  82 1322-1326
• 96 Yang J, Wu J, Jiang H et al.. Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors.  J Biol Chem. 2002;  277 46035-46042
• 97 Horstrup K, Jablonka B, Honig-Liedl P et al.. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition.  Eur J Biochem. 1994;  225 21-27
• 98 Hauser W, Knobeloch K P, Eigenthaler M et al.. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice.  Proc Natl Acad Sci U S A. 1999;  96 8120-8125
• 99 Waldmann R, Nieberding M, Walter U. Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases.  Eur J Biochem. 1987;  167 441-448
• 100 Schwarz U R, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects.  Thromb Haemost. 1999;  82 1145-1152
• 101 Aleil B, Ravanat C, Cazenave J et al.. Flow cytometric analysis of intra-platelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.  J Thromb Haemost. 2004;  3 85-92
• 102 Sage S O, Yamoah E H, Heemskerk J W. The roles of P(2X1)and P(2T AC)receptors in ADP-evoked calcium signalling in human platelets.  Cell Calcium. 2000;  28 119-126
• 103 Cattaneo M, Lecchi A, Lombardi R. Concomitant activation of both the P2Y1-driven Gq and the P2Y12-driven Gi pathways is necessary for normal ADP-induced mobilization of cytoplasmic calcium. Presented at the ISTH meeting July 13-18, 2003 Burmingham, UK; J Thromb Haemost 2003 suppl 1: PO784
• 104 Fox S C, Behan M W, Heptinstall S. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.  Cell Calcium. 2004;  35 39-46
• 105 Hardy A R, Jones M L, Mundell S J, Poole A W. Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets.  Blood. 2004;  104 1745-1782
• 106 Storey R F, Sanderson H M, White A E et al.. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.  Br J Haematol. 2000;  110 925-934
• 107 Dangelmaier C, Jin J, Smith J B, Kunapuli S P. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway.  Thromb Haemost. 2001;  85 341-348
• 108 Kauffenstein G, Bergmeier W, Eckly A et al.. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin-a phosphoinositide 3- kinase-dependent mechanism.  FEBS Lett. 2001;  505 281-290
• 109 Hirsch E, Bosco O, Tropel P et al.. Resistance to thromboembolism in PI3Kgamma-deficient mice.  FASEB J. 2001;  15 2019-2021
• 110 Li Z, Zhang G, Le Breton G C et al.. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases.  J Biol Chem. 2003;  278 30725-30731
• 111 Jackson S P, Yap C L, Anderson K E. Phosphoinositide 3-kinases and the regulation of platelet function.  Biochem Soc Trans. 2004;  32 387-392
• 112 Kim S, Jin J, Kunapuli S P. Akt activation in platelets depends on Gi signaling pathways.  J Biol Chem. 2004;  279 4186-4195
• 113 Woulfe D, Jiang H, Mortensen R et al.. Activation of Rap1B by G(i) family members in platelets.  J Biol Chem. 2002;  277 23382-23390
• 114 Lova P, Paganini S, Sinigaglia F et al.. A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets.  J Biol Chem. 2002;  277 12009-12015
• 115 Larson M K, Chen H, Kahn M L et al.. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets.  Blood. 2003;  101 1409-1415
• 116 Lova P, Paganini S, Hirsch E et al.. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B.  J Biol Chem. 2003;  278 131-138
• 117 Bos J L, de Rooij J, Reedquist K A. Rap1 signalling: adhering to new models.  Nat Rev Mol Cell Biol. 2001;  2 369-377
• 118 Bertoni A, Tadokoro S, Eto K et al.. Relationships between Rap1b, affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton.  J Biol Chem. 2002;  277 25715-25721
• 119 Jin J, Kunapuli S P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.  Proc Natl Acad Sci U S A. 1998;  95 8070-8074
• 120 Léon C, Freund M, Ravanat C et al.. Key role of the P2Y(1) receptor in tissue factor-induced thrombin- dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist.  Circulation. 2001;  103 718-723
• 121 Léon C, Ravanat C, Freund M et al.. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.  Arterioscler Thromb Vasc Biol. 2003;  23 1941-1947
• 122 Dorsam R T, Tuluc M, Kunapuli S P. Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets.  J Thromb Haemost. 2004;  2 804-812
• 123a Baurand A, Eckly A, Bari N et al.. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.  Thromb Haemost. 2000;  84 484-491
• 123b Baurand A, Eckly A, Hechler B et al.. Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties?.  Mol Pharmocol. 2005;  67 721-733
• 124 Roald H E, Sakariassen K S. Axial dependence of collagen-induced thrombus formation in flowing non-anticoagulated human blood. Anti-platelet drugs impair thrombus growth and increase platelet-collagen adhesion.  Thromb Haemost. 1995;  73 126-131
• 125 Roald H E, Barstad R M, Kierulf P et al.. Clopidogrel-a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions.  Thromb Haemost. 1994;  71 655-662
• 126 Goto S, Tamura N, Handa S. Effects of adenosine 5′-diphosphate (ADP) receptor blockade on platelet aggregation under flow.  Blood. 2002;  99 4644-4646
• 127 Remijn J A, Wu Y P, Jeninga E H et al.. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood.  Arterioscler Thromb Vasc Biol. 2002;  22 686-691
• 128 Turner N A, Moake J L, McIntire L V. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow.  Blood. 2001;  98 3340-3345
• 129 Andre P, LaRocca T, Delaney S M et al.. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.  Circulation. 2003;  108 2697-2703
• 130 Conley P B, Delaney S M. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.  Curr Opin Hematol. 2003;  10 333-338
• 131 Moake J L, Turner N A, Stathopoulos N A et al.. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin.  Blood. 1988;  71 1366-1374
• 132 Cattaneo M, Zighetti M L, Lombardi R, Mannucci P M. Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP.  Br J Haematol. 1994;  88 826-829
• 133 Cattaneo M, Lombardi R, Bettega D et al.. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine.  Arterioscler Thromb. 1993;  13 393-397
• 134 Goto S, Tamura N, Sakakibara M et al.. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation.  Platelets. 2001;  12 406-414
• 135 Goto S, Tamura N, Eto K et al.. Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate.  Circulation. 2002;  105 2531-2536
• 136 Resendiz J C, Feng S, Ji G et al.. Purinergic P2Y12 receptor blockade inhibits shear-induced platelet phosphatidylinositol 3-kinase activation.  Mol Pharmacol. 2003;  63 639-645
• 137 MacKenzie A B, Mahaut-Smith M P, Sage S O. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets.  J Biol Chem. 1996;  271 2879-2881
• 138 Vial C, Hechler B, Leon C et al.. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines.  Thromb Haemost. 1997;  78 1500-1504
• 139 Clifford E E, Parker K, Humphreys B D et al.. The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes.  Blood. 1998;  91 3172-3181
• 140 Scase T J, Heath M F, Allen J M et al.. Identification of a P2X1 purinoceptor expressed on human platelets.  Biochem Biophys Res Commun. 1998;  242 525-528
• 141 Sun B, Li J, Okahara K, Kambayashi J. P2X1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression.  J Biol Chem. 1998;  273 11544-11547
• 142 Wang L, Ostberg O, Wihlborg A K et al.. Quantification of ADP and ATP receptor expression in human platelets.  J Thromb Haemost. 2003;  1 330-336
• 143 Vial C, Pitt S J, Roberts J et al.. Lack of evidence for functional ADP-activated human P2X1 receptors supports a role for ATP during hemostasis and thrombosis.  Blood. 2003;  102 3646-3651
• 144 Rosa J P. P2X1: definitely not an ADP receptor.  Blood. 2003;  102 3466-3467
• 145 Mahaut-Smith M P, Ennion S J, Rolf M G, Evans R J. ADP is not an agonist at P2X(1) receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets.  Br J Pharmacol. 2000;  131 108-114
• 146 Savi P, Bornia J, Salel V et al.. Characterization of P2 × 1 purinoreceptors on rat platelets: effect of clopidogrel.  Br J Haematol. 1997;  98 880-886
• 147 Takano S, Kimura J, Matsuoka I, Ono T. No requirement of P2X1 purinoceptors for platelet aggregation.  Eur J Pharmacol. 1999;  372 305-309
• 148 Rolf M G, Mahaut-Smith M P. Effects of enhanced P2X1 receptor Ca2+ influx on functional responses in human platelets.  Thromb Haemost. 2002;  88 495-502
• 149 Toth-Zsamboki E, Oury C, Cornelissen H et al.. P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation.  J Biol Chem. 2003;  278 46661-46667
• 150 Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts M F. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen.  Blood. 2002;  100 2499-2505
• 151 Oury C, Kuijpers M J, Toth-Zsamboki E et al.. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype.  Blood. 2003;  101 3969-3976
• 152 Toth-Zsamboki E, Oury C, Watanabe H et al.. The intracellular tyrosine residues of the ATP-gated P2X(1) ion channel are essential for its function.  FEBS Lett. 2002;  524 15-19
• 153 Mulryan K, Gitterman D P, Lewis C J et al.. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors.  Nature. 2000;  403 86-89
• 154 Vial C, Rolf M G, Mahaut-Smith M P, Evans R J. A study of P2X(1) receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors.  Br J Pharmacol. 2002;  135 363-372
• 155 Sage S O, Rink T J. The kinetics of changes in intracellular calcium concentration in fura- 2-loaded human platelets.  J Biol Chem. 1987;  262 16364-16369
• 156 Kawa K. Thrombopoietin enhances rapid current responses mediated by P2X1 receptors on megakaryocytic cells in culture.  Jpn J Physiol. 2003;  53 287-299
• 157 Erhardt J A, Pillarisetti K, Toomey J R. Potentiation of platelet activation through the stimulation of P2X1 receptors.  J Thromb Haemost. 2003;  1 2626-2635
• 158 Hulsmann M, Nickel P, Kassack M et al.. NF449, a novel picomolar potency antagonist at human P2X1 receptors.  Eur J Pharmacol. 2003;  470 1-7
• 159 Braun K, Rettinger J, Ganso M et al.. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.  Naunyn Schmiedebergs Arch Pharmacol. 2001;  364 285-290
• 160 Kassack M U, Braun K, Ganso M et al.. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.  Eur J Med Chem. 2004;  39 345-357